World Journal of
Pharmaceutical and Life Sciences

POTENTIAL FOR INCREASING EFFECTIVENESS OF POPULAR DIABETES WEIGHT LOSS DRUGS

Manoj Rathore, Meenakshi Panchal, Kajal Agrawal, Pratibha Parmar and Sonu Prajapati*

ABSTRACT

The rising prevalence of diabetes and obesity has fueled interest in therapeutic agents that address both conditions concurrently. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual agonists targeting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) have demonstrated efficacy in managing glycemic control and inducing significant weight loss. However, there is substantial potential for improving their effectiveness through innovative strategies. this review explores emerging approaches, including drug modification for enhanced receptor selectivity, sustained-release formulations for improved adherence, and personalized medicine techniques to optimize patient outcomes. Advances in combination therapies—integrating diabetes weight-loss drugs with other metabolic agents—are also examined. Moreover, the role of novel delivery systems, such as microneedles and oral peptide technology, in increasing drug bioavailability and patient compliance is highlighted. this work underscores the need for deeper insights into the molecular pathways and genetic predispositions influencing drug response. Expanding the effectiveness of diabetes weight-loss drugs not only promises better clinical outcomes but also addresses critical public health challenges associated with obesity and metabolic disorders.

[Full Text Article]   [Download Certificate]